Author

M. Manczinger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Evolutionary Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:proteomics· 2 Organism:bacteria (other)· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:comparative / phylogenetic analysis· 1

Frequent Co-Authors

B. Papp· 3 shared C. Pal· 3 shared B. Koncz· 2 shared B. T. Papp· 2 shared L. Kemeny· 2 shared A. Daraba· 1 shared A. Dunai· 1 shared A. T. Fulop· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

B. Papp

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Antibiotics of the future are prone to resistance in Gram-negative pathogens

L. Daruka, M. S. Czikkely, P. Szili, Z. Farkas, D. Balogh, G. Grezal, E. Maharramov, T.-H. Vu, L. Sipos, S. Juhasz, A. Dunai, A. Daraba, M. Szamel, T. Sari, T. Stirling, , C. Pal

This study shows new antibiotics are as likely to face resistance as existing ones in Gram-negative bacteria, highlighting the need for narrow-spectrum therapies.

bioRxiv · Jul 23, 2023Microbiology

Synergy of HLA class I and II shapes the timing of antitumor immune response

B. T. Papp, A. T. Fulop, G. M. Balogh, B. Koncz, D. Spekhardt, M. Manczinger

The paper examines how combinations of HLA class I and II variants affect antitumor immune response timing and patient survival in melanoma.

bioRxiv · Nov 16, 2022 · PreprintCancer Biology

Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumour immunity

M. Manczinger, G. Balogh, B. T. Papp, B. Koncz, L. Asztalos, L. Kemeny, B. Papp, C. Pal

The paper finds that HLA-I alleles with high peptide binding promiscuity are associated with worse prognosis in cancer patients treated with immune checkpoint inhibitors.

bioRxiv · Jun 25, 2020Cancer Biology

Pathogen diversity drives the evolution of promiscuous peptide binding of human MHC-II alleles

M. Manczinger, G. Boross, L. Kemeny, V. Muller, T. Lenz, B. Papp, C. Pal

This study shows that pathogen diversity drives the evolution of promiscuous peptide binding in human MHC-II alleles, explaining their global distribution and immune function.

bioRxiv · Jul 17, 2018Evolutionary Biology